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Original Article

Buprenorphine for the Treatment
of the Neonatal Abstinence Syndrome
Walter K. Kraft, M.D., Susan C. Adeniyi‑Jones, M.D., Inna Chervoneva, Ph.D.,
Jay S. Greenspan, M.D., Diane Abatemarco, Ph.D., Karol Kaltenbach, Ph.D.,
and Michelle E. Ehrlich, M.D.

A BS T R AC T
BACKGROUND

Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication.
METHODS

In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opioids
in utero and who had signs of the neonatal abstinence syndrome to receive either
sublingual buprenorphine or oral morphine. Infants with symptoms that were not
controlled with the maximum dose of opioid were treated with adjunctive phenobarbital. The primary end point was the duration of treatment for symptoms of
neonatal opioid withdrawal. Secondary clinical end points were the length of
hospital stay, the percentage of infants who required supplemental treatment with
phenobarbital, and safety.
RESULTS

The median duration of treatment was significantly shorter with buprenorphine
than with morphine (15 days vs. 28 days), as was the median length of hospital
stay (21 days vs. 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered in 5 of 33 infants (15%) in the buprenorphine group and in
7 of 30 infants (23%) in the morphine group (P = 0.36). Rates of adverse events
were similar in the two groups.
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CONCLUSIONS

Among infants with the neonatal abstinence syndrome, treatment with sublingual
buprenorphine resulted in a shorter duration of treatment and shorter length of
hospital stay than treatment with oral morphine, with similar rates of adverse
events. (Funded by the National Institute on Drug Abuse; BBORN ClinicalTrials.gov
number, NCT01452789.)
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he neonatal abstinence syndrome
is defined as the occurrence of signs and
symptoms of neonatal withdrawal after in
utero drug exposure.1 Among drug exposures,
opioids cause severe symptoms, including autonomic instability, tremor, irritability, poor feeding, and loose stool. Measures that improve symptom control include minimization of stimulation,
rooming in,2 breast-feeding,3 and frequent calorically dense feedings. Approximately two thirds
of infants with this condition do not have a response to behavioral approaches and ultimately require pharmacologic therapy for control of
symptoms.4
The administration of an opioid at an appropriate dose for symptom control with subsequent
weaning has been identified as an effective approach, but data are limited to guide the choice
of opioid.5 Morphine is used in more than 80%
of the infants who require treatment for the
neonatal abstinence syndrome in the United
States.4 In adults, sublingual buprenorphine is
used to reduce symptoms of opioid withdrawal.6
Buprenorphine has a wide therapeutic index for
respiratory depression and a long half-life that
may make it useful for treatment of the neonatal
abstinence syndrome. Open-label investigations
have established a pharmacokinetic profile in neonates7 and suggested favorable safety and efficacy for this indication.8,9 In the single-site, randomized, double-blind, double-dummy Blinded
Buprenorphine or Neonatal Morphine Solution
(BBORN) trial, we compared sublingual buprenorphine with oral morphine with respect to the duration of treatment in infants with the neonatal
abstinence syndrome.

Me thods
Trial Design and Population

From October 31, 2011, to May 29, 2016, we
enrolled term infants (≥37 weeks of gestation)
who had been exposed to opioids in utero and
had signs and symptoms of the neonatal abstinence syndrome. Exclusion criteria were a major
congenital malformation, a birth weight of less
than 2200 g, a serious medical or neurologic illness, hypoglycemia requiring intravenous glucose,
a bilirubin level of more than 20 mg per deciliter
(342 μmol per liter), maternal use of a benzodiazepine 30 days before birth, or seizures. Breast-
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feeding was an exclusionary criterion until the
approval of a protocol amendment on October
17, 2013. This expansion was driven by changing
local and national4 practice patterns during the
trial, which increased the number of women
who attempted to breast-feed. Written informed
consent was obtained from the parents.
The trial was approved by the institutional
review board at Thomas Jefferson University.
The drug manufacturer, Indivior, donated the
buprenorphine that was used in the trial but was
not involved in the trial design, in the collection,
analysis, or interpretation of the data, or in the
preparation of the manuscript. The protocol,
which includes the statistical analysis plan, is
available with the full text of this article at
NEJM.org.
Treatment

We monitored all infants for the severity of the
neonatal abstinence syndrome using the MOTHER
NAS scale, a modified Finnegan scoring instrument,10 which ranges from 0 to 42 (typical range
in practice, approximately 2 to 14), with higher
scores indicating greater severity. (Details regarding this scale are provided in Table S1 in the Supplementary Appendix, available at NEJM.org.)
Scoring on this scale was performed every 4 hours
for a minimum of 72 hours. The threshold for
pharmacologic treatment was a sum of three scores
of 24 or more or a single score of 12 or more.
Infants for whom treatment was required
were randomly assigned in a 1:1 ratio to receive
either sublingual buprenorphine or oral morphine
and the corresponding placebo. Randomization
was stratified according to maternal exposure to
methadone or buprenorphine and the maternal
intention to breast-feed or bottle-feed.
The dose and regimen of buprenorphine were
derived from efficacy, pharmacokinetic, and safety data generated in a phase 1 trial.8,9 Buprenorphine was administered at a dose of 0.075 mg per
milliliter of solution in simple syrup and 30%
ethanol, which is stable for at least 7 days at room
temperature.11 Placebo for buprenorphine contained no ethanol (1.75 ml of simple syrup in
2.25 ml of sterile water). The dose of morphine
was based on the standard-of-care protocol at
Thomas Jefferson University Hospital (Table S10
in the Supplementary Appendix). Morphine at a
dose of 0.4 mg per milliliter was formulated
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with the use of an oral solution of 4 mg per milli
liter (Roxane) and dilution with sterile water,
which is stable for at least 60 days at room temperature.12 Placebo for morphine was sterile water
mixed with blue dye.
Buprenorphine or placebo was administered
sublingually every 8 hours by a syringe under the
tongue. A pacifier was placed in the infant’s
mouth to maximize contact time with the sublingual mucosa. For doses in which the volume
was greater than 0.5 ml, buprenorphine or placebo was given in two administrations separated
by at least 2 minutes. Morphine or placebo was
administered orally every 4 hours.
Doses of buprenorphine or morphine were
adjusted according to disease severity. After the
first four infants had undergone randomization
(three in the buprenorphine group and one in
the morphine group), we amended the protocol
to change the rate of increase in the morphine
dose from 10% to 20% to match changes in the
hospital standard of care (Fig. S1 in the Supplementary Appendix). After infants had symptom
stability for at least 48 hours, doses were decreased by 10% once per day if the sum of three
scores was less than 18. The investigational-drug
pharmacist notified the clinical team when the
cessation dose had been reached. Infants were
observed in the hospital for at least 48 hours
after the last dose of a trial medication was administered. A rescue dose after cessation of therapy could be given in a blinded manner at the
discretion of the treating physician in any infant
with a score of 12 or more.
The maximum dose was 60 μg per kilogram
of body weight per day for buprenorphine and
1.2 mg per kilogram per day for morphine (Table S2 in the Supplementary Appendix). The maximum dose in the two groups was reached after
six increases in dose, which maintained blinding. If disease stability was not obtained at the
maximum opioid dose, phenobarbital was initiated with a loading dose of 20 mg per kilogram,
followed by a daily oral dose of 5 mg per kilogram per day. When the opioid was weaned to
50% of the highest dose, phenobarbital was decreased to 2.5 mg per kilogram per day. After
three additional steps in opioid weaning, phenobarbital was discontinued and the opioid was
weaned until the cessation dose was reached.
Liver-function testing was performed before or

n engl j med

soon after the initiation of a trial drug and at 7 and
21 days after the initiation of therapy.
End Points

The primary end point was the duration of treatment for neonatal withdrawal symptoms in days
from the first dose of a trial drug. Secondary
clinical end points were the length of hospital
stay (including all levels of care), the percentage
of infants who required supplemental treatment
with phenobarbital, and safety. Exploratory end
points included respiratory rate and weight gain.
Other end points that are not discussed here included pharmacokinetic measurements of bupre
norphine and morphine (secondary outcomes) and
pharmacogenetic, neurobehavioral, and feedingdysfunction measures (exploratory outcomes).
Statistical Analysis

The primary analysis was performed according
to the intention-to-treat principle. On the basis
of the results of previous open-label trials, we
determined that a sample size of 40 infants in
each trial group would provide a power of 90%
to detect a 28% shorter duration of treatment in
the buprenorphine group than in the morphine
group (a difference of 0.323 on a log scale), assuming a common standard deviation of 0.44.
Owing to slower-than-anticipated patient recruitment, the data and safety monitoring board
agreed to a suggestion from the investigators
to stop enrollment before the recruitment of 80
infants.
The randomization was stratified according
to the mother’s intended feeding pattern (bottlefeeding vs. breast-feeding) and maternal use of
buprenorphine versus methadone. However, only
3 infants whose mothers were receiving bupre
norphine underwent randomization (1 in the
buprenorphine group and 2 in the morphine
group) and all were bottle-fed, so stratification
of the analysis according to maternal use of
buprenorphine was not meaningful. Therefore,
statistical tests were adjusted only for the type of
feeding. Neither the duration of treatment nor
the log-transformed duration of treatment was
consistent with normal distribution assumptions.
Therefore, a stratified two-sample van Elteren
test13 (an extension of the Wilcoxon rank-sum
test) was used to compare the duration of treatment and the length of hospital stay in the two
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Table 1. Characteristics of the Infants and Their Mothers at Baseline.*
Characteristic

Buprenorphine
(N = 33)

Morphine
(N = 30)

38.5 (37.0–42.0)

39.0 (37.0–41.0)

Infants
Median gestational age (range) — wk

3040 (2270–4380)

3004 (2197–3850)

Male sex — no. (%)

Median birth weight (range) — g

17 (52)

18 (60)

Breast-feeding subgroup — no. (%)†

12 (36)

9 (30)

Median Apgar score (range)
1

8 (3–9)

8 (5–10)

2

9 (7–9)

9 (7–10)

White

28 (85)

24 (80)

Black

5 (15)

4 (13)

Other

0

2 (7)

Median head circumference (range) — cm

33.0 (30.0–36.5)

33.0 (27.5–36.5)

Age at treatment initiation (range) — days

2 (1–9)

2 (1–14)

32 (97)

27 (90)

130 (25–265)

135 (30–260)

Race — no. (%)‡

Mothers
Use of methadone
Maintenance therapy — no. (%)
Daily dose (range) — mg
Use of buprenorphine
Maintenance therapy — no. (%)

1 (3)

2 (7)

8

7 (6–8)

0

1 (3)

Any

28 (85)

28 (93)

More than 5 cigarettes per day

22 (67)

22 (73)

Cocaine

1 (3)

5 (17)

Amphetamine

1 (3)

0

Other opioid

3 (9)

5 (17)

Daily dose (range) — mg
Use of short-acting opioid — no. (%)
Use of tobacco — no. (%)

Drugs identified on urine screening — no. (%)

*	There were no significant differences between the groups except for median gestational age (P = 0.03).
†	Stratification according to breast-feeding or bottle-feeding was determined by the mother’s intent at the time of randomization; actual behavior after randomization was variable.
‡	Race was reported by the mothers.

groups after adjustment for differences in the
type of feeding. A Cochran–Mantel–Haenszel test
was used to evaluate the association between trial
group and the use of supplemental phenobarbital,
stratified according to the type of feeding.
No interim analysis was performed. For the
exploratory end points of respiratory rate and
weight gain and post hoc safety assessment of
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heart rate before and during treatment, longitudinal data were modeled in a linear mixed-effects
model with the time trends represented by loworder polynomials in postnatal days, with the
polynomial coefficients dependent on fixed effects
of drug and feeding type and random effects of
between-patient variation. When appropriate, the
variance components were estimated separately
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121 Infants had informed consent

58 Did not undergo randomization
56 Did not require pharmacologic therapy
1 Received antibiotics before treatment
for withdrawal
1 Was discharged and readmitted for
treatment before team was notified

63 Underwent randomization

33 Were assigned to receive buprenorphine
(intention-to-treat population)

30 Were assigned to receive morphine
(intention-to-treat population)

3 Were withdrawn by parent
and received open-label
morphine

2 Were withdrawn by parent
and received open-label
morphine

30 Were included in per-protocol
population

28 Were included in per-protocol
population

Figure 1. Enrollment and Outcomes.

for each group. The degrees of freedom were
computed with the use of the approach of Kenward and Roger.14 The tests were not adjusted for
multiplicity because of their exploratory nature.
All tests were two-sided. Statistical analyses were
performed with the use of SAS software, version
9.4 (SAS Institute), and R software (R Foundation
for Statistical Computing).

R e sult s
Patients

Of the 121 singleton infants who underwent
screening, 63 were eligible for pharmacologic
therapy and were enrolled (Table 1 and Fig. 1).
Mothers were predominantly enrolled in an outpatient methadone treatment program. On the
basis of maternal self-declaration of feeding plans,
21 infants were assigned to the breast-feeding
subgroup (12 in the buprenorphine group and
9 in the morphine group). The median duration
of breast-feeding while receiving a trial drug was
7 days (range, 0 to 42) during a median duration
of treatment of 23 days. At the time of hospital
discharge, 9 of 21 infants (43%) were breast-fed.

n engl j med

Six infants (29%) were breast-fed for no more
than 2 days before their mothers decided to
switch exclusively to bottle feeding.
After randomization, the parents of 5 infants
withdrew consent for participation in the trial.
In 4 infants (2 in the buprenorphine group and
2 in the morphine group), the parental concern
was based on the slow duration of the weaning
process. In the buprenorphine group, a parent
decided to withdraw 1 infant after two doses of
the trial drug were administered. No withdrawals
were due to adverse events. After withdrawal from
the trial, all the infants were treated with openlabel morphine according to the same treatment
protocol.
In the intention-to-treat analysis, 33 infants
were included in the buprenorphine group and
30 infants in the morphine group. In the perprotocol analysis, 5 infants who had undergone
randomization were excluded from the analysis
because of withdrawal of consent. Thus, the perprotocol analysis included 30 infants in the buprenorphine group and 28 infants in the morphine group. In the as-treated analysis, 3 infants
who had been assigned to the buprenorphine
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Table 2. Primary and Secondary Outcomes (Intention-to-Treat Population).
Outcome and Feeding Subgroup

Buprenorphine
(N = 33)

Morphine
(N = 30)

Difference
(95% CI)*

P Value

days
No. of infants
Bottle-feeding

21

21

Breast-feeding

12

9

Primary outcome
Median duration of treatment (range) — days

15 (3 to 67)

28 (13 to 67)

−13 (−21 to −7)

Bottle-feeding

15 (3 to 67)

28 (13 to 67)

−13 (−23 to −6)

Breast-feeding

20 (3 to 55)

28 (16 to 52)

−8 (−30 to 2)

<0.001†

Secondary outcomes
Median length of hospital stay (range) — days

21 (7 to 71)

33 (18 to 70)

−12 (−22 to −7)

Bottle-feeding

21 (7 to 71)

33 (18 to 70)

−12 (−23 to −7)

Breast-feeding

26 (7 to 58)

32 (20 to 58)

−8 (−29 to 2)

5 (15)

7 (23)

Bottle-feeding

2 (6)

4 (13)

Breast-feeding

3 (9)

3 (10)

Use of supplemental phenobarbital — no. (%)

<0.001†

0.36‡

*	The difference between the buprenorphine group and the morphine group was calculated with the use of the Hodges–Lehmann estimator
as the median of all paired differences between observations in the two groups with the corresponding nonparametric 95% confidence interval (CI).
†	This P value was calculated by means of the van Elteren test.
‡	This P value was calculated by means of the Cochran–Mantel–Haenszel test.

group but had withdrawal of consent were included in the morphine group. Thus, 30 infants
were included in the buprenorphine group and
33 infants in the morphine group in the astreated analysis.
Primary and Secondary End Points

In the intention-to-treat analysis, the median duration of treatment was 15 days in the buprenorphine group and 28 days in the morphine group,
a difference of 13 days (95% confidence interval
[CI], 7 to 21; P<0.001). The median length of
hospital stay was 21 days in the buprenorphine
group and 33 days in the morphine group, a difference of 12 days (95% CI, 7 to 22; P<0.001)
(Table 2 and Fig. 2). The duration of treatment
and length of hospital stay were also significantly shorter in the buprenorphine group than
in the morphine group in both the per-protocol
analysis and the as-treated analysis (P<0.001 for
both comparisons) (Tables S3 and S4 in the Supplementary Appendix).
The use of supplemental phenobarbital was
required in 5 of 33 infants (15%) in the bu-
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prenorphine group (2 in the bottle-feeding subgroup and 3 in the breast-feeding subgroup) and
in 7 of 30 infants (23%) in the morphine group
(4 in the bottle-feeding subgroup and 3 in the
breast-feeding subgroup) (P = 0.36). No infants
were readmitted to the hospital after discharge.
In a sensitivity analysis, the primary finding was
materially unchanged when the 3 infants who
were assigned to the buprenorphine group but
subsequently received morphine were hypothetically assumed to have a duration of treatment
equal to the maximum of all observed values
instead of actually observed values (P<0.001).
Safety

Overall, 13 adverse events occurred in 7 infants in
the buprenorphine group and 10 events in 8 infants in the morphine group (P = 0.79 for the
number of events by Fisher’s exact test) (Table 3). There were two serious adverse events.
One was an inguinal hernia repair in the morphine group and one was a supraglottoplasty
associated with the Pierre Robin syndrome in
the buprenorphine group. There were no eleva-
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A Duration of Treatment
80

Duration of Treatment (days)

tions in levels of alanine aminotransferase or
aspartate aminotransferase in any infant. The
mean respiratory rate in the morphine group
was lower by 4.4 breaths per minute (95% CI, 0.7
to 8.1) than in the buprenorphine group in the
same feeding subgroup (P = 0.02), although all
the respiratory rates were within the normal
range. At 7 days, the mean reduction in weight
from birth was less in the morphine group than
in the buprenorphine group (167 g vs. 231 g,
P = 0.04). There were no significant betweengroup differences in the change from birth
weight or in heart rates at days 14, 21, and 28.

70
60
50
40
30
20
10
0

Morphine,
bottle-feeding

Buprenorphine,
bottle-feeding

Morphine,
breast-feeding

Buprenorphine,
breast-feeding

Drug and Type of Feeding

Discussion

B Length of Hospital Stay

n engl j med

80

Length of Hospital Stay (days)

In this single-center, randomized trial involving
63 infants with the neonatal abstinence syndrome, we found that buprenorphine was significantly more effective than morphine in reducing the duration of treatment, with a median
between-group difference of 13 days in the
intention-to-treat analysis. This difference translated into a similarly significant reduction in the
length of hospital stay. Results were similar in
the per-protocol analysis and the as-treated analysis. We found no significant differences between
groups in the need for adjunctive phenobarbital
treatment, although few infants in either group
received this treatment. These findings suggest
that the pharmacodynamic effects of buprenorphine and morphine may not differ substantially at the predefined maximal doses.
The frequency of adverse events was similar
in the two groups. Infants in the morphine group
had a lower respiratory rate than those in the
buprenorphine group. This potential advantage,
along with a longer interval between doses, may
allow for investigation of buprenorphine in outpatient settings, a use that was not examined in
this trial.
Limitations of the trial include the small
sample size and the single-center design. Also,
since we excluded preterm infants and those
with in utero exposure to benzodiazepines, our
results should not be generalized to infants with
such characteristics. Buprenorphine has been
used in critically ill preterm infants,15 but its
utility in preterm infants with the neonatal abstinence syndrome has not been defined. Preterm
infants have a decreased incidence and severity

70
60
50
40
30
20
10
0

Morphine,
bottle-feeding

Buprenorphine,
bottle-feeding

Morphine,
breast-feeding

Buprenorphine,
breast-feeding

Drug and Type of Feeding

Figure 2. Duration of Treatment and Length of Hospital Stay.
The duration of treatment (Panel A) and length of hospital stay (Panel B)
were shorter in the buprenorphine group than in the morphine group
(P<0.001 for both comparisons). Randomization was stratified according
to the type of intended feeding method (bottle-feeding or breast-feeding).
The box-and-whisker plots represent medians (horizontal lines) and interquartile ranges (top and bottom of the boxes); the I bars represent the
maximum or minimum value or 1.5 times the interquartile range. Outliers
are indicated by circles.

of withdrawal signs,16-18 and it is unclear whether
the standard scoring instruments that we used
would be valid in this population. Exposure to
benzodiazepines in utero is associated with
worsened symptoms of neonatal abstinence. The
use of buprenorphine in infants with benzodiazepine exposure is currently being investigated in
other clinical trials (ClinicalTrials.gov numbers,
NCT02249026 and NCT01671410).
The mechanisms by which buprenorphine allows for a shorter duration of treatment than
morphine are unclear. It is possible that the long
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Table 3. Adverse Events.
Buprenorphine
(N = 33)

Event

Morphine
(N = 30)

no. of events
Serious adverse events
Inguinal hernia repair

0

1

Supraglottoplasty

1

0

Any

13

10

Anemia

1

0

Skin condition

5

3

Gastrointestinal condition

3

3

Respiratory infection

0

2

Cough

1

0

Tachycardia

1

0

Umbilical granuloma

1

0

Urinary tract infection

0

1

Other adverse events
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effective than oral morphine in reducing the duration of treatment for the neonatal abstinence
syndrome, which translated into a shorter hospital stay. The two drugs had similar safety profiles.
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